Evolva starts Phase I Clinical Trials on EV-077

Basel, Switzerland, 18 March 2009 – Evolva SA, an international biotech company focused on the discovery and development of drugs based on its genetic chemistry platform, today announced it has started Phase I Clinical Trials with its drug candidate EV-077–3201–2TBS.

The first-in-man study, a single ascending dose study, will enroll 56 healthy male volunteers and will be conducted in Germany over the next 12 weeks. The purpose of the study is to assess the safety and tolerability of EV-077–3201–2TBS and evaluate its pharmacokinetic profile and pharmacodynamic effects.

Dr. Alexandra Santana Sorensen, VP R&D of Evolva said: “We are very pleased and excited to have reached a significant Milestone by entering Phase I studies with our first drug candidate. We believe that EV-077–3201–2TBS has a very interesting potential in a number of cardiovascular and renal indications.”

EV-077–3201–2TBS is a new chemical entity, with a different mode of action from existing drugs that are being developed for cardiovascular and renal indications.

About Evolva

Evolva uses its genetic chemistry platform to replicate, on an industrial basis, the ability of nature to create small molecules with exquisite “design”. Based on this technology, the Company has a number of third party discovery and pre-clinical programs. Evolva’s drug development activities focus on cardiovascular, renal and infectious diseases. The Company had revenues of about CHF 10 million in 2008. For more information see www.evolva.com.

Contact Details

Alexandra Santana Sorensen
alexandras@evolva.com
Phone: +41 61 485 20 20
Fax: +41 61 485 20 01